Artiva Biotherapeutics, Inc.

In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Under the lead

With the rapid growth in the global cell and gene therapy (CGT) market, South Korean pharma firms have increasingly been diversifying into the contract manufacturing area for these novel modalities vi

Actuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest

Artiva Biotherapeutics, Inc. ’s initial public offering late on 18 July reflected the mixed bag that the IPO market has become. To get the offering through the IPO window at a time when first-time off